about
Asymptomatic ventricular preexcitation: a long-term prospective follow-up study of 293 adult patients.Clinical characteristics, management, and prognosis of elderly patients with Brugada syndrome.The clinical impact of ajmaline challenge in elderly patients with suspected atrioventricular conduction disease.Drug-induced brugada syndrome in children: clinical features, device-based management, and long-term follow-up.Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience.Clinical characterisation and long-term prognosis of women with Brugada syndrome.Advanced techniques for chronic lead extraction: heading from the laser towards the evolution system.Prognostic value of programmed electrical stimulation in Brugada syndrome: 20 years experience.On the Quest for the Best Freeze: Predictors of Late Pulmonary Vein Reconnections After Second-Generation Cryoballoon Ablation.Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study.One Year Incidence of Atrial Septal Defect after PV Isolation: A Comparison Between Conventional Radiofrequency and Cryoballoon Ablation.Persistence of Phrenic Nerve Palsy Following 28-mm Cryoballoon Ablation: A Four-Year Single Center Experience.New-onset atrial fibrillation as first clinical manifestation of latent Brugada syndrome: prevalence and clinical significance.One year incidence of iatrogenic atrial septal defect after cryoballoon ablation for atrial fibrillation.Life-threatening ventricular arrhythmias during ajmaline challenge in patients with Brugada syndrome: incidence, clinical features, and prognosis.Initial experience of three-minute freeze cycles using the second-generation cryoballoon ablation: acute and short-term procedural outcomes.Predictors of advanced lead extraction based on a systematic stepwise approach: results from a high volume center.Pulmonary vein isolation in patients with Brugada syndrome and atrial fibrillation: a 2-year follow-up.P-wave indices as predictors of atrial fibrillation recurrence after pulmonary vein isolation in normal left atrial size.Impact on Clinical Outcome of Premature Interruption of Cryoenergy Delivery Due to Phrenic Nerve Palsy During Second Generation Cryoballoon Ablation for Paroxysmal Atrial Fibrillation.Incidence and characteristics of complications in the setting of second-generation cryoballoon ablation: A large single-center study of 500 consecutive patients.Intermittent alternance of Brugada ECG patterns: Insights from a unique electrophysiological phenomenon.Single 3-Minute versus Double 4-Minute Freeze Strategy for Second-Generation Cryoballoon Ablation: A Single-Center Experience.Asymptomatic Brugada Syndrome: Clinical Characterization and Long-Term Prognosis.Comparison between radiofrequency with contact force-sensing and second-generation cryoballoon for paroxysmal atrial fibrillation catheter ablation: a multicentre European evaluation.Complications in the setting of percutaneous atrial fibrillation ablation using radiofrequency and cryoballoon techniques: A single-center study in a large cohort of patients.Spontaneous and adenosine-induced pulmonary vein reconnection after cryoballoon ablation with the second-generation device.One-year follow-up after single procedure Cryoballoon ablation: a comparison between the first and second generation balloon.Second-generation cryoballoon ablation for paroxysmal atrial fibrillation: 1-year follow-up.Circumferential pulmonary vein isolation as index procedure for persistent atrial fibrillation: a comparison between radiofrequency catheter ablation and second-generation cryoballoon ablation.Electrophysiological findings following pulmonary vein isolation using radiofrequency catheter guided by contact-force and second-generation cryoballoon: lessons from repeat ablation proceduresReplyRegular atrial tachycardias following pulmonary vein isolation for paroxysmal atrial fibrillation: a retrospective comparison between the cryoballoon and conventional focal tip radiofrequency techniquesPulmonary vein isolation as index procedure for persistent atrial fibrillation: One-year clinical outcome after ablation using the second-generation cryoballoonFollow-up From Childhood to Adulthood of Individuals With Family History of Brugada Syndrome and Normal ElectrocardiogramsPeriprocedural outcomes of prophylactic protamine administration for reversal of heparin after cryoballoon ablation of atrial fibrillationComparison of the patient-activated event recording system vs. traditional 24 h Holter electrocardiography in individuals with paroxysmal palpitations or dizzinessComparison of Pulmonary Vein Isolation Using Cryoballoon Versus Conventional Radiofrequency for Paroxysmal Atrial FibrillationTowards a tailored cryo-pulmonary vein isolation. Lessons learned from second-generation cryoballoon ablationAtrial fibrillation progression and management: a 5-year prospective follow-up study
P50
Q33157907-FAE7E078-2B48-4985-9C3C-66A1EAB2143CQ33163709-1D3C2EE8-DD9C-463E-9FC3-923A94A7B374Q33163775-75DCD729-BBA1-438B-A824-C51F93B7E2E3Q33164037-D20D5A59-546D-487A-AFC6-73C6197179B8Q33165377-3CF85D82-72E6-4427-B70A-2EBBEC024D98Q33166655-0B0D6D33-479A-4E94-955A-172D47075CD8Q34706521-3B083698-F526-4A3B-B803-6A85EDA39EA6Q39014965-BE33C705-5EDB-49A6-A3BE-2D6F76540CE7Q40363557-E73A3019-2F41-4C5E-8FD5-46DC7313BAC2Q40534372-6C789B56-3756-4DE8-AC20-8D0515B869CAQ40939888-15CB8936-1E4A-454C-A77E-899B05726361Q41103694-D7860657-B267-4B88-8966-863E791A310BQ43288607-6FB873D8-B1D5-4E77-BA2F-97039666EAABQ43644309-8CCA5B81-2631-46A3-9768-0F6D7190D950Q44189708-07FC9D53-6CAE-419A-B942-4567F80F3DA4Q44283442-43A5897A-6BBE-4B5C-9191-D9439CAD40D4Q44763903-805C1D3D-5A30-4633-8226-A94FFCEAD9F9Q45223897-47D8E743-FB47-4637-9E7F-300A342A8999Q47419619-B0BBDE55-6971-4CD2-9540-2673D7570946Q47699286-77A72C4B-B2D8-43DA-B189-AD356D5A49CDQ47724955-961D3208-CD22-496C-853E-0284180DA3ADQ48190408-53963366-9E33-40E1-8A9A-93345D41D850Q50862695-71CC61F6-3722-4C7B-9D89-F8FB0BE2E524Q51285213-F5DED2AE-5715-4381-85EB-7FDC3F11DF11Q53272188-82AE2B66-A5A2-4634-AC6B-807E95A1E6EDQ53465644-B6EA42DC-DABD-46F0-8F62-8460D8888468Q53587751-401F6F56-CA31-4D7E-BB14-1A498C8E7C5DQ53595916-02314D42-9A90-4A19-AC6B-2F5677C7E10CQ53629763-29A7EA7E-6E96-4AC1-AC7D-D03203BA0F60Q53639423-4512E005-06D4-4AAC-A1CD-C898EEC898ADQ57676554-0EF28A1C-6AC9-4DC8-B743-71B948DFCBACQ57676573-61B5413E-F124-49AC-BBB0-A7AE2A199F42Q57676577-EE1B60BB-DB46-4F75-82DE-5FAD2DF82200Q57676578-9F7DB164-26AA-4C93-A31D-617D2D8C3577Q57676579-E7BEA00A-2E11-4686-A664-1D6FC8F5A41BQ57676582-2C78FF19-CF48-495F-A2C1-2CA0AF545677Q57676584-65D3F3AD-851C-42BB-ACA9-17A8448C6A49Q57676587-2A385A68-CDB1-431A-B776-C2306BFD6C7AQ64038734-F13E1848-72AD-433E-B013-2CCA8A658BB1Q82239927-77399264-2DEA-40F9-9199-A020AD02C333
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giuseppe Ciconte
@ast
Giuseppe Ciconte
@en
Giuseppe Ciconte
@es
Giuseppe Ciconte
@nl
Giuseppe Ciconte
@sl
type
label
Giuseppe Ciconte
@ast
Giuseppe Ciconte
@en
Giuseppe Ciconte
@es
Giuseppe Ciconte
@nl
Giuseppe Ciconte
@sl
prefLabel
Giuseppe Ciconte
@ast
Giuseppe Ciconte
@en
Giuseppe Ciconte
@es
Giuseppe Ciconte
@nl
Giuseppe Ciconte
@sl
P1053
J-9938-2016
P106
P1153
25121125300
P21
P31
P496
0000-0001-7886-5467